{"title":"皮下泛膜炎样t细胞淋巴瘤患者的临床特征和预后。","authors":"Yaobin Lin, Shenghong Shi, Jiahui Wu, Shan Liu","doi":"10.1080/14737140.2025.2517280","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Subcutaneous panniculitis-like T-cell lymphoma (SPTCL) is a rare and highly heterogeneous cytotoxic T-cell lymphoma with unknown epidemiology, clinical features, and prognosis.</p><p><strong>Methods: </strong>We retrospectively analyzed data on patients with SPTCL from the Surveillance, Epidemiology, and End Results database (2000-2021). Joinpoint plots of incidence were created. Independent prognostic factors for overall survival (OS) and lymphoma-specific survival (LSS) were analyzed using univariate Cox regression analysis. Kaplan - Meier analyses were performed to assess survival.</p><p><strong>Results: </strong>Among 258 included patients, we observed an increase in the overall incidence of SPTCL, particularly among individuals aged ≥ 50. The age at SPTCL onset exhibited a unimodal distribution, with peak incidence in the 60-69-year age group. Multivariate Cox regression analysis indicated that diagnoses made between 2000 and 2006, as well as age ≥ 50, were associated with reduced OS and LSS. We describe a case of primary maxillofacial SPTCL in a pediatric patient at our center.</p><p><strong>Conclusions: </strong>SPTCL has unique clinical and pathological characteristics and tends to occur in younger patients. Early identification and active treatment are beneficial for improving prognosis and survival.</p>","PeriodicalId":12099,"journal":{"name":"Expert Review of Anticancer Therapy","volume":" ","pages":"973-981"},"PeriodicalIF":2.8000,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Clinical characteristics and outcomes among patients with subcutaneous panniculitis-like T-cell lymphoma.\",\"authors\":\"Yaobin Lin, Shenghong Shi, Jiahui Wu, Shan Liu\",\"doi\":\"10.1080/14737140.2025.2517280\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Background: </strong>Subcutaneous panniculitis-like T-cell lymphoma (SPTCL) is a rare and highly heterogeneous cytotoxic T-cell lymphoma with unknown epidemiology, clinical features, and prognosis.</p><p><strong>Methods: </strong>We retrospectively analyzed data on patients with SPTCL from the Surveillance, Epidemiology, and End Results database (2000-2021). Joinpoint plots of incidence were created. Independent prognostic factors for overall survival (OS) and lymphoma-specific survival (LSS) were analyzed using univariate Cox regression analysis. Kaplan - Meier analyses were performed to assess survival.</p><p><strong>Results: </strong>Among 258 included patients, we observed an increase in the overall incidence of SPTCL, particularly among individuals aged ≥ 50. The age at SPTCL onset exhibited a unimodal distribution, with peak incidence in the 60-69-year age group. Multivariate Cox regression analysis indicated that diagnoses made between 2000 and 2006, as well as age ≥ 50, were associated with reduced OS and LSS. We describe a case of primary maxillofacial SPTCL in a pediatric patient at our center.</p><p><strong>Conclusions: </strong>SPTCL has unique clinical and pathological characteristics and tends to occur in younger patients. Early identification and active treatment are beneficial for improving prognosis and survival.</p>\",\"PeriodicalId\":12099,\"journal\":{\"name\":\"Expert Review of Anticancer Therapy\",\"volume\":\" \",\"pages\":\"973-981\"},\"PeriodicalIF\":2.8000,\"publicationDate\":\"2025-08-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Expert Review of Anticancer Therapy\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1080/14737140.2025.2517280\",\"RegionNum\":3,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2025/6/7 0:00:00\",\"PubModel\":\"Epub\",\"JCR\":\"Q2\",\"JCRName\":\"ONCOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Expert Review of Anticancer Therapy","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/14737140.2025.2517280","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/6/7 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"ONCOLOGY","Score":null,"Total":0}
Clinical characteristics and outcomes among patients with subcutaneous panniculitis-like T-cell lymphoma.
Background: Subcutaneous panniculitis-like T-cell lymphoma (SPTCL) is a rare and highly heterogeneous cytotoxic T-cell lymphoma with unknown epidemiology, clinical features, and prognosis.
Methods: We retrospectively analyzed data on patients with SPTCL from the Surveillance, Epidemiology, and End Results database (2000-2021). Joinpoint plots of incidence were created. Independent prognostic factors for overall survival (OS) and lymphoma-specific survival (LSS) were analyzed using univariate Cox regression analysis. Kaplan - Meier analyses were performed to assess survival.
Results: Among 258 included patients, we observed an increase in the overall incidence of SPTCL, particularly among individuals aged ≥ 50. The age at SPTCL onset exhibited a unimodal distribution, with peak incidence in the 60-69-year age group. Multivariate Cox regression analysis indicated that diagnoses made between 2000 and 2006, as well as age ≥ 50, were associated with reduced OS and LSS. We describe a case of primary maxillofacial SPTCL in a pediatric patient at our center.
Conclusions: SPTCL has unique clinical and pathological characteristics and tends to occur in younger patients. Early identification and active treatment are beneficial for improving prognosis and survival.
期刊介绍:
Expert Review of Anticancer Therapy (ISSN 1473-7140) provides expert appraisal and commentary on the major trends in cancer care and highlights the performance of new therapeutic and diagnostic approaches.
Coverage includes tumor management, novel medicines, anticancer agents and chemotherapy, biological therapy, cancer vaccines, therapeutic indications, biomarkers and diagnostics, and treatment guidelines. All articles are subject to rigorous peer-review, and the journal makes an essential contribution to decision-making in cancer care.
Comprehensive coverage in each review is complemented by the unique Expert Review format and includes the following sections:
Expert Opinion - a personal view of the data presented in the article, a discussion on the developments that are likely to be important in the future, and the avenues of research likely to become exciting as further studies yield more detailed results
Article Highlights – an executive summary of the author’s most critical points.